Lv71
4308 积分 2021-04-15 加入
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
5小时前
待确认
Bispecific T cell engager therapy for refractory rheumatoid arthritis
21天前
已完结
The IL‐17 pathway as a major therapeutic target in autoimmune diseases
24天前
已完结
Targeting IL-17 in autoimmunity and inflammation
24天前
已完结
An FDA oncology analysis of immune activating products and first-in-human dose selection
24天前
已完结
Prevalence of psoriasis in China: A population-based study in six cities
24天前
已完结
Interleukin-17 and innate immunity in infections and chronic inflammation
24天前
已完结
Biocompatible Recombinant Type III Collagen Enhancing Skin Repair and Anti-Wrinkle Effects
9个月前
已完结
Recombination humanized type III collagen promotes oral ulcer healing
9个月前
已完结
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus
10个月前
已完结
皖公网安备34019202002308
